Hepatocellular Carcinoma Treatment and Prognosis

Organoids grew from 13 of 27 resected hepatocellular carcinomas. The sequenced lines kept parental mutations, and solid rather than cystic growth marked shorter progression-free survival (HR 13.91).

This study identifies BRIX1 as a promoter of hepatocellular carcinoma progression through the MAPK/ERK pathway and shows its potential as a prognostic biomarker.

This paper identifies a distinct HCC subgroup defined by high regeneration-associated stress, showing vulnerability to ATR inhibitors and proposing LIVRESS as a biomarker for treatment stratification.

The paper identifies proliferation-specific genes in liver cancer by integrating transcriptomic, functional genomics, and clinical data, finding 26 genes with strong dependency scores and poor patient survival association.

This study uses spatial transcriptomics to compare the tumor-stroma border in HBV-related and NBNC HCC, identifying conserved desmoplastic niches and etiology-specific immune signaling differences.

This paper shows that combining LDN57444 with low-dose sorafenib enhances anti-tumor effects in hepatocellular carcinoma by reversing drug-induced adaptive responses.

This study shows that reducing GPC3 in liver cancer cells increases their sensitivity to radiation by extending G2/M arrest and activating the ATM/CHK2 pathway, with clinical evidence linking high GPC3 to worse outcomes in radiotherapy-treated HCC patients.

This paper develops a niclosamide sulfate prodrug, SSL-0024, which improves solubility and bioavailability, showing strong anti-tumor effects against hepatocellular carcinoma through multiple pathway inhibition.

This study investigates NABP2's role in HCC by analyzing its expression, immune microenvironment, and metabolic pathways, identifying potential therapeutic targets.

This study develops a hydrogel for treating hepatocellular carcinoma that improves embolization and drug delivery, showing better tumor growth reduction than standard treatments.

This paper evaluates transcriptomic similarities between liver cancer cell lines and primary tumors to guide model selection and identify authentication issues.

This study identifies T1D-related genes associated with HCC prognosis using gene expression datasets and statistical analysis.

This paper identifies ADAMTS3 as a novel serum biomarker for hepatocellular carcinoma with strong diagnostic performance and demonstrates a DNA origami-based SERS biosensor for its detection.

This study identifies clinical and molecular features of primary refractoriness to atezolizumab plus bevacizumab in HCC, showing poor outcomes and an immunosuppressive tumor microenvironment.

This study identifies gender-specific proteomic signatures in DEN-induced HCC by comparing differentially expressed proteins in male and female mice, revealing distinct pathways and prognostic markers.

This study identifies FSTL1's role in promoting vascular mimicry in HCC via interaction with PDCD4 and activation of the PI3K/AKT/mTOR pathway, suggesting it as a potential therapeutic target.

This study compares the chemotoxic effects of idarubicin and doxorubicin in HCC models, finding differential impacts on fibrosis, stellate cell activation, and ER-stress pathways.

This study investigates SSTR2 overexpression in HCC, finding it correlates with poor survival and oncogenic pathways, suggesting it as a therapeutic target and theranostic biomarker.

The paper shows that LC4 cells derived from HCV-related HCC replicate the transcriptomic features of the parental tumor, including immune suppression and metabolic changes.

The paper identifies two liver cancer subtypes using multi-omics data, develops a prognostic model with superior accuracy, and validates findings through single-cell analysis.

This study compares liquid embolic (LE) and particle embolic (PE) in transarterial embolization (TAE) for hepatocellular carcinoma (HCC) in rats, finding LE induces greater tumor necrosis and improved treatment response.

This study characterizes the tumor microenvironment of steatotic liver-related hepatocellular carcinoma using single-cell and spatial transcriptomic analyses, identifying immunosuppressive features and Treg-CAF interactions linked to immunotherapy resistance.

The paper validates the HepatoPredict kit's analytical performance for HCC prognosis before liver transplantation, showing robustness and accuracy in identifying patients who benefit from the procedure.

This study identifies the transcriptional changes and signaling pathways affected by ARHGEF2 inhibition in hepatocellular carcinoma cells, highlighting AD and CS pathways and key interacting genes.

This study investigates the oncogenic roles and clinical significance of DCTN1-6 in LIHC using multi-omics data, finding their differential expression, methylation, mutation, and association with survival and immune infiltration.

The paper identifies key molecules and signaling pathways in Sorafenib-treated hepatocellular cancer cells using RNA-seq data analysis.

The paper develops a prognostic model using multi-omics data to stratify HCC patients into recurrence risk groups, identifying key RNA, miRNA, and methylation features with significant predictive performance.

This study evaluates lenvatinib's efficacy and safety as second/third-line treatment for unresectable HCC after sorafenib, showing higher response rates and survival in earlier lines and better liver function.